Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
This cohort study showed that, during the 2022 to 2023 season, infection with SARS-CoV-2 was associated with more severe disease outcomes than influenza or RSV, whereas differences were less pronounced during the 2023 to 2024 season. During both seasons, RSV remained a milder illness, whereas COVID-19 was associated with higher long-term mortality. Vaccination attenuated differences in disease severity and long-term mortality.
Authors
- Lei Yan (ORCID: https://orcid.org/0000-0002-4779-2688)
- George N. Ioannou (ORCID: https://orcid.org/0000-0003-1796-8977)
- Mihaela Aslan (ORCID: https://orcid.org/0000-0002-5041-010X)
- Kristin Berry (ORCID: https://orcid.org/0009-0000-7372-7727)
- Nallakkandi Rajeevan (ORCID: https://orcid.org/0000-0002-2045-0872)
- David Bui (ORCID: https://orcid.org/0000-0003-0861-0850)
- Kristina L. Bajema (ORCID: https://orcid.org/0000-0002-3229-5590)
- Yuli Li (ORCID: https://orcid.org/0000-0003-1364-8562)
- Yuan Huang
- Hung‐Mo Lin
- Robert Vergun
Institutions
- Oregon Health & Science University (US)
- University of Washington (US)
- Yale University (US)
- VA Connecticut Healthcare System (US)
- VA Puget Sound Health Care System (US)
- VA Portland Health Care System (US)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1001/jamainternmed.2024.7452
- Citations
- 33
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 44.69